PION PION 深 滬
等待開盤 10-28 09:30:00 美东时间
0.00
0.000
NaN.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.00
- 總市值 0
- 52周最高 0.00
- 市盈率 靜 --
- 換手率 NaN.00%
- 52周最低 0.00
- 委 比 0.00%
- 總股本 0
- 歷史最高 0.00
- 量 比 0
- 振 幅 NaN.00%
- 歷史最低 0.00
- 每 手 1
- 風險率
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki
<p>Oculis Holding AG has completed enrollment in the PREDICT-1 trial of Licaminlimab, a gene-targeted precision medicine for dry eye disease (DED), with 176 patients, 2/3 of whom have a specific TNFR1 genotype linked to improved clinical response. Licaminlimab aims to address unmet needs in DED treatment by targeting patients with TNFR1-mediated disease, potentially offering the first precision therapy for approximately 1.5 million affected indiv...
10-19 06:00
KESPION Extends KRW 1.35 Billion Debt Guarantee for Vietnamese Subsidiary
KESPION Co. Ltd. ( ($KR:079190) ) has provided an update. KESPION Co. Ltd. has ...
10-16 13:50
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
Oculis Holding AG has initiated the PIONEER-1 trial to evaluate Privosegtor for optic neuritis (ON), with the first patient treated in the U.S. Privosegtor, a novel neuroprotective agent, showed promising results in the Phase 2 ACUITY trial, leading to FDA Breakthrough Therapy and EMA PRIME designations. The trial aims to assess visual recovery and safety, with potential broader applications in neurology, including acute multiple sclerosis relaps...
08-24 08:00
Oculis 2026年第二季度财报：净亏损收窄，现金可支撑至2029年下半年
Oculis 2026年第二季度补助收入31万瑞郎，每股亏损0.16瑞郎，净亏损降至997万瑞郎；期末现金及短期投资2.283亿瑞郎，预计可支持运营至2029年下半年。
08-07 01:11
Oculis Reports Q2 2026 Financial Results and Provides Company Update
Oculis Holding AG reported Q2 2026 results, highlighting progress in its neuro-ophthalmology pivot with Privosegtor advancing in optic neuritis and potential expansion into acute MS relapses following positive FDA feedback. Licaminlimab's PREDICT-1 trial for dry eye disease is on track with over 45% patient enrollment. The company has $282.3 million in cash, providing runway into H2 2029. Upcoming milestones include R&D Day for Privosegtor and to...
08-06 20:05
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
Oculis Holding AG announced positive FDA pre-IND feedback for Privosegtor in acute multiple sclerosis (MS) relapses. The FDA supports the regulatory pathway and confirms existing data can be used for an IND submission in the fourth quarter of 2026. Privosegtor, a neuroprotective candidate, has shown promise in optic neuritis and aims to address unmet needs in MS relapse treatment. Oculis plans to host an R&D Day later this year to provide further...
08-03 08:00
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
Oculis Holding AG will present at Clinical Trials at the Summit 2026 in Las Vegas, discussing Privosegtor, a novel neuroprotective therapy for optic neuritis (ON). Privosegtor, a peptoid small molecule, can cross both the blood-brain and retinal barriers, targeting unmet needs in ON and other optic neuropathies. The company has achieved significant milestones, including Breakthrough Therapy designation from the FDA and PRIME designation from the ...
06-11 08:00
